Latest News for: interval ratio

Edit

RYBREVANT®▼ (amivantamab) plus LAZCLUZE®▼ (lazertinib) demonstrates significant overall survival benefit in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations versus osimertinib

Pharmiweb 31 Mar 2025
At a median follow-up of 37.8 months, patients treated with first-line amivantamab plus lazertinib had a significantly longer OS compared to those receiving the current standard of care, osimertinib ...
Edit

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

Pharmiweb 31 Mar 2025
... progression, recurrence, not undergoing surgery, or death versus the comparator arm (based on event-free survival [EFS] hazard ratio [HR] of 0.68; 95% confidence interval [CI] 0.56-0.82; p<0.0001).
Edit

New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Pharmiweb 26 Mar 2025
... OS benefit with&nbsp;Tagrisso compared to placebo in patients with unresectable, Stage III EGFRm NSCLC (hazard ratio [HR] 0.67; 95% confidence interval [CI] 0.40, 1.14, maturity 31%).
  • 1
×